Chul Kim
Hematology & Oncology · Washington, DCNPI 1841586302
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $144,176 of the $173,032 with a category attached, or 83.3%. It is spread thinly across 23 manufacturers, the largest accounting for just 18.0%. 2025 is the largest year on record at $64,694, more than ten times the $1,041 reported in 2019. Among hematology & oncology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $852.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$31K
- AstraZeneca$19K
- Johnson & Johnson$17K
- EMD Serono, Inc.$17K
- Boehringer Ingelheim International GmbH$15K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- plus $59K from 17 others
Across 231 payments — averaging $35,725 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$2.2M
- Daiichi Sankyo Inc.$2M
- AstraZeneca$1.9M
- Boehringer Ingelheim$899K
- Janssen Research & Development, LLC$390K
- Genentech, Inc.$178K
- plus $645K from 13 others
What the payments were for
- Consulting fees$144,17683%
- Speaking & faculty fees$13,2378%
- Travel & lodging$10,8636%
- Food & beverage$4,7573%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 55 | $31,213 |
| AstraZeneca | 32 | $19,392 |
| Johnson & Johnson | 27 | $17,273 |
| EMD Serono, Inc. | 5 | $16,662 |
| Boehringer Ingelheim International GmbH | 11 | $14,803 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $14,495 |
| Sanofi | 13 | $12,183 |
| Daiichi Sankyo Inc. | 11 | $12,165 |
| Janssen Scientific Affairs, LLC | 7 | $7,805 |
| E.r. Squibb & Sons, L.L.C. | 5 | $7,778 |
| Bayer | 4 | $4,453 |
| Partner Therapeutics, Inc. | 10 | $4,418 |
| Boehringer Ingelheim | 4 | $3,783 |
| Jazz Pharmaceuticals Inc. | 1 | $3,200 |
| Pfizer | 1 | $1,300 |
| Novartis | 2 | $740 |
| Eisai Inc. | 1 | $645 |
| Novocure Inc. | 2 | $203 |
| Caris MPI, Inc. | 1 | $191 |
| Regeneron Healthcare Solutions, Inc. | 3 | $137 |
| Amgen | 2 | $116 |
| Genentech USA, Inc. | 2 | $46 |
| Angiodynamics, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$173,032 in reported general payments places this provider in the 90th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 57 | $954,316 |
| EliquisApixaban | 39 | $25,277 |
| Enoxaparin Sodium | 13 | $3,991 |
| Erlotinib Hcl | 22 | $2,770 |
| Oxycodone Hcl | 46 | $528 |
| Ondansetron Hcl | 37 | $514 |
| Dexamethasone | 26 | $455 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $350 |
| Gabapentin | 31 | $332 |
| Prochlorperazine Maleate | 16 | $260 |
| Pantoprazole Sodium | 12 | $177 |
| Hydrocortisone | 23 | $154 |
| Atorvastatin Calcium | 18 | $121 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 13 | $120 |
| Prednisone | 50 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $19,392 | $954,31657 claims |
| PfizerEliquis | $1,300 | $25,27739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
- Faysal HarounWashington$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.